ArticleFrontiers in genetics2025
Comparative RNA-seq and functional assays identify L-arginine transporter SLC7A2 as a potential regulator of osteogenesis in maxillary sinus mucosal stem cells.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The osteogenic differentiation of maxillary sinus mucosal stem cells (MSMSCs) plays a critical role in maxillary sinus floor elevation, yet its underlying regulatory mechanisms remain unclear. In addition, although both MSMSCs and palatal mesenchymal stem cells (PMSCs) may participate in bone regeneration, their osteogenic differentiation characteristics and molecular regulation differences have not been systematically analyzed. Therefore, the study aimed to characterize the transcriptional differences between MSMSCs and PMSCs during osteogenesis and identify the role of solute carrier family 7 member 2 (SLC7A2) in MSMSCs' osteogenic differentiation. Methods: RNA sequencing (RNA-Seq) was conducted to compare gene expression profiles of MSMSCs and PMSCs at baseline (day 0) and 7, 14, and 21 days after osteogenic induction. Osteogenic differentiation was evaluated using Alkaline Phosphatase (ALP) staining, Alizarin Red S (ARS) staining, Western blotting, and quantitative polymerase chain reaction (qPCR) for the osteogenic markers osteocalcin (OCN), runt-related transcription factor 2 (RUNX2), and bone morphogenetic protein 2(BMP2). A lentiviral-based SLC7A2-silencing model was established in MSMSCs to silence SLC7A2 expression and thereby investigate its role in osteogenic differentiation. Results: MSMSCs and PMSCs exhibited similar osteogenic gene expression patterns, but their underlying regulatory mechanisms differed. Notably, amino acid metabolism-related pathways were significantly enriched in MSMSCs during osteogenesis. SLC7A2 was identified as one of the top 10 differentially expressed genes (DEGs) common to MSMSCs at baseline (day 0) and 7, 14, and 21 days after osteogenic induction (FDR <0.05 and |log Conclusion: The osteogenic differentiation of MSMSCs is tightly associated with amino acid metabolism.Notably, SLC7A2-an L-arginine transporter-is a gene required for the efficient osteogenic differentiation of MSMSCs. This study provides novel evidence to advance our understanding of the molecular mechanisms underlying stem cell osteogenic differentiation during maxillary sinus floor lifting surgery,and further suggests that SLC7A2 may serve as a potential target to enhance the efficacy of MSMSCs-based bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.